Especially patients with inflammatory joint diseases like rheumatoid arthritis suffer from excessive RANKL expression and enhanced bone resorption [35], making it therefore a therapeutical target in these patients [36]. This evidence concerns the gene TNFSF11 and rheumatoid arthritis.